The company’s initial public offering price was several times higher than previously expected: A prospectus filed with the SEC in August proposed an IPO of $100 million. At $39 per share, however, and with 10 million shares in the offering, 10x Genomics’ actual IPO could amount up to $390 million.
Upon its stock market debut, the company, trading under the symbol TXG, opened at $54 per share and peaked at $58 per share. According to Barron’s, this performance places 10x Genomics’ valuation around $5.2 billon, well above the $1.28 billion figure estimated by Forbes earlier this year.
More articles on health IT:
Email wire fraud has cost $26B in losses in 3 years, FBI finds: 4 things to know
UnitedHealthcare accelerator chooses 10 digital health startups for inaugural cohort
GE Healthcare’s AI X-ray device 1st to receive FDA clearance
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
